Avalyn Pharma CEO Lyn Baranowski reports sale of common shares worth $1.46 million
AVLN•Avalyn Pharma CEO and director Lyn Baranowski sold 52,500 common shares on Nov. 17-18, 2026, for weighted-average prices of $27.7604 to $29.2249 per share after exercising options at $4.62 per share.
1. Share sale
Baranowski sold 52,500 common shares and exercised stock options for the same number of shares at $4.62 each. After the transactions, she held no common shares directly and retained 610,833 stock options.




